Laquinimod is a novel once-daily, orally administered immunomodulatory compound developed as a disease modifying treatment for   more »

A short-term, very-high dose regimen of the immune-suppressing drug cyclophosphamide seems to slow progression of multiple sclerosis (MS) in most of a small group of patients studied and   more »

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a cell therapy development and commercialization company, announced favourable safety and efficacy data for Tovaxin®, the Company's investigational T-cell vaccination   more »

Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary   more »

A new type of pill for relapsing-remitting multiple sclerosis (MS) has led to a 40 percent reduction in lesions and inflammation. The experts are hoping that the oral medication, which goes by the name laquinimod, could potentially be a significant advance, a   more »

Recently Human Genome Sciences (HGS) stated they were going ahead with several of their new drugs and they are planning to test LymphoStat-B, an experimental lupus drug, on Multiple Sclerosis (MS). The company feels the drug may also be effective on   more »

BaroFold Inc. announced that it has initiated a two-stage Phase 1, repeat dosing, single-center, double-blinded study in up to sixty healthy volunteers to determine the safety, tolerability,   more »

The trial is designed to evaluate the safety and efficacy of MBP8298 in patients with secondary progressive MS. The trial is a randomized, double-blind study with the primary clinical endpoint defined as a statistically and clinically significant increase   more »

In Phase I trials, researchers test an experimental drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify   more »

Can a participant leave a clinical trial after it has begun? Yes. A participant can leave a clinical trial, at any time. When withdrawing from the trial, the participant should let the research team know about it, and the reasons for leaving the   more »

This study demonstrated that all doses were safe and well tolerated, and demonstrated early immunological effects of PI-2301 consistent with its pharmacologic mechanism of action.   more »

There are risks to clinical trials. · There may be unpleasant, serious or even life-threatening side effects to experimental treatment. · The experimental treatment may not be effective for   more »

Choosing to participate in a clinical trial is an important personal decision. The following frequently asked questions provide detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members, or friends about   more »

Choosing to participate in a clinical trial is an important personal decision. The following frequently asked questions provide detailed information about clinical trials. In addition, it is often helpful to talk to a physician, family members, or friends about   more »

Use of skin patches containing the drug rotigotine can relieve restless legs syndrome (RLS) during both the day and night. These are the conclusions of authors of an article to be   more »